Magnolia Medical Technologies

Magnolia Medical Technologies is on a mission to deliver breakthrough solutions that advance diagnostic accuracy to support better clinical decisions and improve patient outcomes. The company developed the Steripath® Micro Initial Specimen Diversion Device®, which is FDA 510(k)-cleared with a specific indication to reduce blood culture contamination for sepsis testing accuracy.

In 2006, Dr. Richard Patton, former Chief of Pathology at UW Medicine / Northwest Hospital & Medical Center and the co-founder of Magnolia Medical Technologies Inc., designed a clinical study to test the effectiveness of Initial Specimen Diversion Technique (ISDT®), an innovation that he conceived earlier in his career. He went on to author the seminal manuscript on the efficacy of initial specimen diversion for blood culture collection. This study was published in the Journal of Clinical Microbiology in 2010. Magnolia Medical Technologies patented initial specimen diversion for blood culture collection, both the technique, ISDT®, and the technology, Initial Specimen Diversion Device® (ISDD®).

• Steripath® Micro Initial Specimen Diversion Device®

  FDA 510(k)-cleared with a specific indication to reduce blood culture contamination for sepsis testing accuracy.

• 2021-10-26

  Magnolia Medical appoints Joseph Bishop as SVP[5]Magnolia Medical任命Joseph Bishop为高级副总裁prnewswire.com

  Reported: 2021-10-26

  Magnolia Medical Technologies announced that Joseph Bishop joined its executive leadership team as Senior Vice President of Operations and Product Development. Bishop is responsible for the Operations, Product Development, Quality Assurance, and Regulatory Affairs teams.

1. 1Magnolia Medical Technologies I Makers of Steripath® Micromagnolia-medical.com
2. 2History of Magnolia Medical Technologies and Steripathmagnolia-medical.com
3. 3Leadership - Magnolia Medicalmagnolia-medical.com
4. 4Mission to ZERO™ - False-Positives End With Usmagnolia-medical.com
5. 5Magnolia Medical任命Joseph Bishop为高级副总裁prnewswire.com